Skip to main content
Premium Trial:

Request an Annual Quote

UAB Heads Partnership Focusing on Patient Care for Mitochondrial Diseases

NEW YORK (GenomeWeb) – The University of Alabama at Birmingham, the Foundation for Mitochondrial Medicine, and Seahorse Bioscience today announced a partnership to improve care for mitochondrial diseases.

The Foundation for Mitochondrial Medicine Program at UAB will be a comprehensive clinical program for diagnosis and treatment of neuromuscular mitochondrial diseases based on personalized medicine. It will comprise a monthly clinic to evaluate and care for patients with mitochondrial disease as well as a reference laboratory.

With bioenergetics testing from UAB enabled by Seahorse's instrumentation, clinicians will apply the advances in metabolic and genetic analysis to the diagnosis and treatment of patients with mitochondrial disorders, the partners said in a statement.

Additionally, the reference laboratory will help evaluate Seahorse's XF Technology and stress test kits, which measure and analyze respiratory complex activities and mitochondrial DNA damage in white blood cells and platelets from blood samples.

Over the first three years, the program hopes to validate and obtain CLIA certification for these tests using the XF platform.

Earlier this month, Agilent Technologies announced it would acquire Seahorse for $235 million.